This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Rare Disease Innovation & Partnership Summit
March 21-23, 2023
Delivered as a Hybrid EventPhiladelphia Marriott Downtown

Everett Crosland
Chief Commercial Officer at Cognito Therapeutics


Everett leads the commercial organization at Cognito Therapeutics, a pioneer in neuromodulation to treat neurodegenerative. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and initiated a pivotal, phase 3 study in December, 2022. As Chief Commercial Officer, Everett leads Cognito's commercial readiness, marketing, sales, and health economic evidence development for the company’s breakthrough treatment portfolio. Everett was previously CCO at AppliedVR and VP of Market Access, Reimbursement & Government Affairs at Pear Therapeutics.

Agenda Sessions

  • Optimize Investment Opportunities in Orphan Drugs